Comparison · NCT00945529-sae
Intervention vs No Intervention/ Historical Control Group: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intervention vs No Intervention/ Historical Control Group: serious adverse events. Trial comparisons, record NCT00945529-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00945529-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.238 | 0.106 | 0.451 | wilson | |
| Risk in group 2 | 0.348 | 0.188 | 0.551 | wilson | |
| Risk difference, group 1 minus group 2 | -0.11 | -0.352 | 0.156 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.685 | 0.265 | 1.77 | log | |
| Odds ratio, group 1 over group 2 | 0.586 | 0.156 | 2.2 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Intervention than on No Intervention/ Historical Control Group | 9.11 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: no intervention.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intervention | Prospective group who received iNO.~inhaled nitric oxide: Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean. | 5 | 21 | EG001 |
| Group 2 | No Intervention/ Historical Control Group | Historical controls group of patients who did not receive iNO. | 8 | 23 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- The Effects of Inhaled Nitric Oxide After Fontan Operation
- NCT number
- NCT00945529
- Phases
- PHASE2, PHASE3
- Conditions
- Congenital Heart Defect
- Interventions
- inhaled nitric oxide (iNO)
- Lead sponsor
- Ellen Spurrier
- Results first posted
- 2023-05-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00945529?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00945529-sae